Establishment of a Cohort of Patients With Sepsis-associated Encephalopathy (SAE)

ConditionSepsis-Associated Encephalopathy

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18-89

SponsorYi Li, MD

About this trial

In this study, the researcher involved the sepsis patients(defined by sepsis 3.0) in Peking Union Medical College Hospital. The SAE was defined as the Glasgow Coma Scale (GCS) score of less than 15 and the Non-SAE group GCS = 15. The control group was the non-infectious patients with acute disease strikes and the healthy control. After the sample collection, the RNA-sequence, metabolites and cytokines were under detection.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

sepsis 3.0 diagnostic criteria;

Estimated length of hospital stay> 24h;

ages 18-89;

Acute brain dysfunction: delirium, coma, epilepsy, focal neurological deficit;

Disqualifiers

Diagnosis of patients with brain injury before admission, including Alzheimer's disease, craniocerebral injury, etc .;

Primary brain injury (cerebral hemorrhage, cerebral infarction, etc.), secondary brain injury (liver brain, lung brain, uremia encephalopathy, pancreatic encephalopathy, metabolic encephalopathy, Wake encephalopathy, etc.);

pregnant and lactating women;

Those who have undergone bypass surgery in the past 3 months;

Trial population

Meet the above three categories of patients consistent with inclusion and exclusion criteria

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

No intervention
Other intervention
No intervention

Treatment groups

3,000 Participants

are divided into 3 treatment groups

Group A: sepsis associated encephalopathy (SAE)1 intervention

Group B: Non-SAE1 intervention

Group C: Control1 intervention

Trial outcomes

Primary outcomes

Finding the pathogenesis of sepsis encephalopathy

To find the pathogenesis of sepsis encephalopathy by genetic testing of blood and cerebrospinal fluid in patients with sepsis and sepsis and SIRS by molecular biomarkers and physiological parameters

Time frame

2020-2030

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Yi Li, MD

Lead sponsor

Peking Union Medical College Hospital

Sponsor institution

Source ClinicalTrials.gov

Apply now